Ocular Myasthenia Gravis

AbstractPurpose of reviewTo review the diagnosis and current treatments for ocular myasthenia gravis (OMG) with a focus on recent advances.Recent findingsNovel microRNA biomarkers show promise in predicting which patients with OMG will subsequently develop generalized disease. Newly developed clinical rating scales may enable more effective OMG-specific research. A recent meta-analysis suggested that treatment with prednisone may reduce the risk of developing generalized myasthenia gravis (GMG) in patients with OMG. Multiple new steroid-sparing immunotherapies, including complement inhibitors and neonatal Fc receptor antibodies, have proven effective in GMG and may be an option in refractory OMG patients.SummaryOcular myasthenia gravis is a rare disease that causes ptosis and diplopia. Many effective therapies exist, and the prognosis is good. Advances continue to be made in the diagnosis and management of OMG.
Source: Current Treatment Options in Neurology - Category: Neurology Source Type: research